Healthcare Biz Recap: Dendreon BOMBS, Cancer Cures Galore

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) pop, following word of positive top-line results in testing on the use of its Xiaflex drug in treating Peyronie’s disease.

Dendreon (NASDAQ:DNDN) shares move markedly down after ASCO conference data from Johnson & Johnson (NYSE:JNJ) and Medivation (NASDAQ:MDVN) seriously ratchet up their rivalry with the former’s Provenge cancer drug. A case in point: patients taking JNJ’s Zytiga in a late-stage pre-chemo prostate cancer study survived 27.2 months compared to 21.7 months with Provenge.

Don’t Miss: 3 BOMBS Getting Dropped on Dendreon Now.

Abbott Labs (NYSE:ABT) views India, with its extensive malnutrition and the largest population of diabetes in the world, as a “growth area”. To that effect, Abbott is opening its first nutrition research and development center, from which it will explore the production of nutrition products, while growing its sales and distribution operations in that country.

Bristol Myers’ (NYSE:BMY) heads up a “revolution in the making” with its BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in a range of 18 to 28 percent of patients. The ‘revolution’, which includes drug firms Merck (NYSE:MRK), Roche (RHHBY.PK), Teva (NASDAQ:TEVA) and GlaxoSmithKline (NYSE:GSK) is at the vanguard of treatments that are designed to enable the body’s immune-system to kill cancer cells.

Investing Insights: Cooper Companies Second Quarter Earnings Sneak Peek.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business